614 Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients

Abstract

BackgroundMicrobiome-based interventions with fecal microbiota transplant (FMT) from treatment responders (R) have shown promising results in re-sensitizing anti-PD-1-refractory melanoma patients to anti-PD1 therapy. However, it is not currently known whether...